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space. METHODS/STUDY POPULATION: Methods: We prospectively
recruited 39 patients undergoing prostatectomy for this institutional review board
(IRB) approved study. Patients underwent MP-MRI before prostatectomy on a 3T
field strength MRI scanner (General Electric, Waukesha, WI, USA) using an
endorectal coil. MP-MRI included field-of-view optimized and constrained
undistorted single shot (FOCUS) diffusion weighted imaging with 10 b-values
(b=0, 10, 25, 50, 80, 100, 200, 500, 1000, and 2000), dynamic contrast enhanced
imaging, and T2-weighted imaging. T2 weighted images were intensity normalized
and apparent diffusion coefficient maps were calculated. The dynamic contrast
enhanced data was used to calculate the percent change in signal intensity before
and after contrast injection. All images were aligned to the T2 weighted image.
Robotic prostatectomy was performed 2 weeks after image acquisition. Prostate
samples were sliced using a 3D printed slicing jig matching the slice profile of the T2
weighted image. Whole mount samples at 10μm thickness were taken,
hematoxylin and eosin stained, digitized, and annotated by a board certified
pathologist. A total of 210 slides were included in this study. Lumen and epithelium
were automatically segmented using a custom algorithm written in MATLAB. The
algorithm was validated by comparing manual to automatic segmentation on 18
samples. Slides were aligned with the T2 weighted image using a nonlinear control
point warping technique. Lumen and epithelium density and the expert annotation
were subsequently transformed into MRI space. Co-registration was validated by
applying a known warp to tumor masks noted by the pathologist and control point
warping the whole mount slide to match the transform. Overlap was measured
using a DICE coefficient. A learning curve was generated to determine the optimal
number of patients to train the algorithm on. A PLS algorithm was trained on 150
random permutations of patients incrementing from 1 to 29 patients. Slides were
stratified such that all slides from a single patient were in the same cohort. Three
cohorts were generated, with tumor burden balanced across all cohort. A PLS
algorithm was trained on 2 independent training sets (cohorts 1 and 2) and applied
to cohort 3. The input vector consisted of MRI values and the target variable was
lumen and epithelium density. The algorithm was trained lesion-wise. Trained PiCT
models were applied to the test cohort voxel-wise to generate 2 new image
contrasts. Mean lesion values were compared between high grade, low grade, and
healthy tissue using an ANOVA. An ROC analysis was performed lesion-wise on
the test set. RESULTS/ANTICIPATED RESULTS: Results: The segmentation
accuracy validation revealed R=0.99 and R=0.72 (p<0.001) for lumen and
epithelium, respectively. The co-registration accuracy revealed a 94.5% overlap.
The learning curve stabilized at 10 patients with a root mean square error of 0.14,
thus the size of the 2 independent training cohorts was set to 10, leaving 19 for the
test cohort. DISCUSSION/SIGNIFICANCEOF IMPACT:We present a technique
for combining radiology and pathology with machine learning for generating
predictive cytological topography (PiCT) maps of cellularity and lumen density
prostate. The voxel-wise approach to mapping cellular features generates 2 new
interpretable image contrasts, which can potentially increase confidence in diagnosis
or guide biopsy and radiation treatment.
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OBJECTIVES/SPECIFIC AIMS: We recently reported that PRMT5 epigenetically
activates androgen receptor (AR) in prostate cancer cells. Because targeting AR
signaling through androgen deprivation therapy is clinically used as a radio-
sensitization approach to treat high-risk prostate cancer, our finding raised an
exciting possibility that targeting PRMT5 may improve RT for prostate cancer
patients. Contrary to our expectation, targeting PRMT5 sensitized both AR
expressing and AR negative (AR− ) prostate cancer cell lines to radiation. The goal
of our study was therefore to determine the role of PRMT5 in repair of IR-induced
DSBs and to translate these findings to improving radiation therapy for cancer
patients in general (not just prostate cancer patients). METHODS/STUDY
POPULATION: The majority of experiments were basic science experiments
analyzing PRMT5’s role in the DNA damage response in normal and cancer cell
lines. For example, to extend our findings and determine if PRMT5’s role in DSB
repair is conserved across multiple cell types, we performed similar experiments in
AR− prostate cancer cells, luminal breast cancer cells, glioblastoma cells, and
human embryonic kidney cells. To determine the clinical significance of our finding,
we also analyzedmRNA expression of PRMT5, AR, and both PRMT5 and AR target
genes involved in DSB repair across 43 clinical cancer data sets. RESULTS/
ANTICIPATED RESULTS: (1) Targeting PRMT5 sensitizes prostate cancer cells to
IR in an AR-independent manner, (2) PRMT5 regulates the repair of IR-induced
DSBs in an AR-independent manner, (3) RNA-seq analysis reveals that PRMT5
likely regulates genes involved in the DNA damage response, (4) PRMT5 activates
expression of several genes in the DDR including those involved in DSB repair, (5)
PRMT5 functions as an epigenetic activator of genes involved in DDR, (6) PRMT5 is
required for NHEJ, HR, and G2-Arrest upon IR treatment, (7) Upregulation of
PRMT5 correlates with formation and repair of IR-induced DSBs, (8) PRMT5’s role
in repair of IR-induced DSBs is conserved in several normal and cancer cell types,
and (9) PRMT5 expression correlates with expression of DSB repair proteins in
clinical cancer samples. DISCUSSION/SIGNIFICANCE OF IMPACT: In summary,
we provide evidence that PRMT5 is a master epigenetic regulator of IR-induced
DSB repair through epigenetic activation of multiple target genes involved both HR
and NHEJ as well as G2 arrest. Interestingly, the majority of genes regulated by
PRMT5 are well-characterized, “core repair proteins” involved in HR (RAD51,
BRCA1, BRCA2, RAD51D, and RAD51AP1), NHEJ (NHEJ1, Ku80, XRCC4, and
DNAPKcs), and G2 arrest (Cdk1, CDC25C, CCNB2, and WEE1), which may
explain why PRMT5 is essential to repair IR-induced DSBs in several cell lines.
Although ARmay also regulate DSB repair via both HR andNHEJ, several pieces of
evidence in our study suggest that PRMT5 also regulates DSB repair independent of
AR. First, PRMT5 targeting sensitizes both AR+ and AR− prostate cancer cells to
IR. Second, exogenous expression of AR only partially rescues the impairment of
IR-induced DSB repair by PRMT5 knockdown. Third, PRMT5 knockdown
increases IR-induced DSB in AR− DU145 cells and several other cancer cell lines
and normal cells. Fourth, PRMT5 expression correlates positively with the
expression of its target genes in multiple human cancer tissues. During preparation
of this project, Braun et al. reported that PRMT5 post-translationally regulates the
splicing out of detained-introns (DI)s of genes to modulate gene expression.
However, analysis of their data showed that the majority of DEGs we identified
either do not contain DIs or DI splicing was not affected by targeting PRMT5. In
addition, Clarke et al. reported that PRMT5 participates in the DSB repair choice
process and promotes HR through methylation of RUVBL1. It is therefore likely
that PRMT5 regulates repair of IR-inducedDSB viamultiplemechanisms. As PRMT5
is overexpressed in many human cancers and its overexpression correlates with
poor prognosis, our findings suggest that increased DSB repair by PRMT5
overexpression in these human cancers may confer survival advantages particularly
following DNA damaging treatment. Because targeting DSB repair has been proven
to be a valid therapeutic approach for cancer treatment, our findings here also
suggest that PRMT5 targetingmay be explored as amonotherapy or in combination
therapy with RT or chemotherapy for cancer treatment.
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OBJECTIVES/SPECIFIC AIMS: We aimed to develop an assay to measure new
protein synthesis after Antisense Oligonucleotide treatment, which we hypothe-
sized to be the earliest biochemical identification of RNA-targeting therapy
efficacy. METHODS/STUDY POPULATION: We treated 2 transgenic animal
models expressing proteins implicated in neurodegenerative disease: human tau
protein (hTau) and human superoxide dismutase 1 (hSOD1), with ASO against
these mRNA transcripts. Animals received isotope-labeled 13C6-Leucine via
drinking water to label newly synthesized proteins. We assayed target protein
synthesis and concentration after ASO treatment to determine the earliest
identification of ASO target engagement. RESULTS/ANTICIPATED RESULTS:
hTau ASO treatment in transgenic mice lowered hTau protein concentration
23 days post-treatment in cortex (95% CI: 0.05%–64.0% reduction). In the same
tissue, we observed lowering of hTau protein synthesis as early as 13 days (95%CI:
29.4%–123%). In hSOD1 transgenic rats, we observed lowering of 13C6-leucine-
labeled hSOD1 in the cerebrospinal fluid 30 days after ASO treatment compared
with inactive ASO control (95% CI: 12.0%–48.4%). DISCUSSION/SIGNIFI-
CANCE OF IMPACT: In progressive neurodegenerative diseases, it is crucial to
develop measurements that identify treatment efficacy early to improve patient
outcomes. These data support the use of stable isotope labeling of amino acids to
measure new protein synthesis as an early pharmacodynamics measurement for
therapies that target RNA and inhibit the translation of proteins.
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OBJECTIVES/SPECIFIC AIMS: The objective of the present study is to
determine if decreased adiponectin and increased leptin levels are associated
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